Anaerobic Performance Neuromuscular Performance Cognitive PerformanceCATAPNCT07466654
Low-Dose Caffeine and Taurine Effects on Performance
A study testing Caffeine, taurine and Caffeine + Taurine in people with Anaerobic Performance Neuromuscular Performance Cognitive Performance, run by Ankara University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate the effects of low-dose caffeine and taurine, administered separately and in combination, on anaerobic, neuromuscular, and cognitive performance. The study is designed as a randomized, double-blind, placebo-controlled crossover trial involving trained man participants. Read more about this study
- Who is it for?
- Ages 18 to 25 years, men only
- Conditions the study is for
- Anaerobic Performance Neuromuscular Performance Cognitive Performance
- What is being tested?
- Caffeine, taurine and Caffeine + Taurine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Oct 2025to 15 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Male participants aged 18 to 25 years
- Regularly engaged in strength training at least three days per week for the previous 24 months
- Apparently healthy with no self-reported cardiovascular, metabolic, neurological, or musculoskeletal disorders
- Free from injuries affecting skeletal muscles, joints, or tendons during the previous two years
Who cannot join
- Use of medications or dietary supplements that may influence physical or cognitive performance
- Known sensitivity or intolerance to caffeine or taurine
- Consumption of caffeine or other stimulants within 24 hours prior to the testing sessions
- Failure to comply with pre-testing instructions or study procedures
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Burdur Mehmet Akif Ersoy University Faculty of Sport Science
Burdur, Merkez, 15100
About this study
Official title: Synergistic Effects of Low-Dose Caffeine and Taurine on Anaerobic, Neuromuscular, and Cognitive Performance: A Double-Blind Randomized Placebo-Controlled Crossover Study
This study aims to investigate the effects of low-dose caffeine and taurine, administered separately and in combination, on anaerobic, neuromuscular, and cognitive performance. The study is designed as a randomized, double-blind, placebo-controlled crossover trial involving trained man participants. Each participant will complete experimental sessions under different supplementation conditions, including caffeine, taurine, their combination, and placebo. Performance outcomes will include anaerobic power, neuromuscular performance, and cognitive function assessments. The findings will help clarify whether the combined ingestion of caffeine and taurine produces synergistic performance effects compared with isolated supplementation.
Read the detailed description
Caffeine and taurine are commonly consumed ingredients in coffee and energy drinks and are frequently used as ergogenic aids to enhance physical and cognitive performance. Although both compounds have been widely investigated individually, evidence regarding their combined effects remains limited and inconsistent. Understanding whether caffeine and taurine produce synergistic or additive effects is important for clarifying their role in sports performance and supplementation strategies.
The present study is designed as a randomized, double-blind, placebo-controlled crossover trial to examine the isolated and combined effects of low-dose caffeine and taurine on anaerobic, neuromuscular, and cognitive performance in trained individuals. Participants will complete multiple experimental sessions under different supplementation conditions, including caffeine, taurine, their combination, and placebo. During each session, participants will undergo standardized performance assessments to evaluate anaerobic power, neuromuscular performance, and cognitive function. The crossover design allows each participant to serve as their own control, minimizing inter-individual variability. The findings of this study may provide further insight into the potential synergistic effects of caffeine and taurine supplementation on performance outcomes.
- Being tested
- Caffeine, taurine, Caffeine + Taurine, Placebo
- Keywords
- caffeine, taurine, wingate, neuromuscular performance, cognitive performance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CaffeineDietary supplement
Also called CAF
Caffeine administered at a dose of 2 mg/kg body mass in capsule form, 60 minutes prior to performance testing.
taurineDietary supplement
Also called TAU
Taurine administered at a dose of 10 mg/kg body mass in capsule form, 60 minutes prior to performance testing.
Caffeine + TaurineDietary supplement
Also called CAF+TAU
Combined supplementation of caffeine (2 mg/kg) and taurine (10 mg/kg) administered 60 minutes prior to testing.
PlaceboDietary supplement
Also called PLA
Placebo capsule containing maltodextrin (300 mg) administered 60 minutes prior to testing.
| Study group | Role | What they receive |
|---|---|---|
| Caffeine | Experimental | Participants receive caffeine at a dose of 2 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation. Receives: Dietary Supplement: Caffeine; Dietary Supplement: Placebo |
| Taurine | Experimental | Participants receive taurine at a dose of 10 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation. Receives: Dietary Supplement: taurine; Dietary Supplement: Placebo |
| Caffeine + Taurine | Experimental | Participants receive a combination of caffeine (2 mg/kg) and taurine (10 mg/kg) in capsule form 60 minutes prior to the performance testing session. Performance assessments include anaerobic, neuromuscular, and cognitive outcomes. Receives: Dietary Supplement: Caffeine + Taurine |
| Plasebo (Maltodextrine 300 mg) | Placebo comparator | Participants receive a placebo capsule containing maltodextrin (300 mg) 60 minutes prior to the performance testing session. The same performance tests are administered to allow comparison with the supplementation conditions. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anaerobic Power
Anaerobic power measured during the Wingate Anaerobic Test following supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo).
Measured: 60 minutes after supplementation
Secondary outcomes (1)
Neuromuscular Performance
Neuromuscular performance assessed using handgrip strength measured with a hand dynamometer following supplementation.
Measured: 60 minutes after supplementation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study start15 Oct 2025
- Primary completion15 Nov 2025
- Study completion15 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anaerobic Performance Neuromuscular Performance Cognitive PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Participants complete multiple experimental sessions under different supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo) in a randomized crossover design. Each participant receives all interventions in separate sessions with appropriate washout periods.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ankara University
- Sponsor type
- University, hospital or other
- Collaborators
- Burdur Mehmet Akif Ersoy University
- Responsible party
- Principal investigator, Yakup Kose, Burdur Mehmet Akif Ersoy University
- Investigators
- Yakup Köse, MsC, Principal investigator, Burdur Mehmet Akif Ersoy University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07466654
- Sponsor's protocol ID
- YK-CAF-TAU-2025
- Other IDs
- YK-CAF-TAU-2025
- Acronym
- CATAP
- Status last verified
- Mar 2026
- First submitted
- 6 Mar 2026
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant-level data will not be publicly shared. Aggregated data supporting the findings of this study may be available from the corresponding author upon reasonable request.
Publications
Kose Y, Ulas M, Atay E. Effects of combined low-dose caffeine and taurine on anaerobic, neuromuscular, and cognitive performance: a double-blind randomized placebo-controlled crossover study. BMC Sports Sci Med Rehabil. 2026 Jul 8. doi: 10.1186/s13102-026-01863-x. Online ahead of print.
PubMed 42421135
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Synergistic Effects of Low-Dose Caffeine and Taurine on Anaerobic, Neuromuscular, and Cognitive Performance: A Double-Blind Randomized Placebo-Controlled Crossover Study
- ClinicalTrials.gov ID
- NCT07466654
- Acronym / sponsor ID
- CATAP / YK-CAF-TAU-2025
- Keywords
- caffeine, taurine, wingate, neuromuscular performance, cognitive performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Ankara UniversityUniversity, hospital or other
- Collaborators
- Burdur Mehmet Akif Ersoy University
- Study start
- 15 Oct 2025 (actual)
- Primary completion
- 15 Nov 2025 (actual)
- Study completion
- 15 Nov 2025 (actual)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the effects of low-dose caffeine and taurine, administered separately and in combination, on anaerobic, neuromuscular, and cognitive performance. The study is designed as a randomized, double-blind, placebo-controlled crossover trial involving trained man participants. Each participant will complete experimental sessions under different supplementation conditions, including caffeine, taurine, their combination, and placebo. Performance outcomes will include anaerobic power, neuromuscular performance, and cognitive function assessments. The findings will help clarify whether the combined ingestion of caffeine and taurine produces synergistic performance effects compared with isolated supplementation.
Detailed description
Caffeine and taurine are commonly consumed ingredients in coffee and energy drinks and are frequently used as ergogenic aids to enhance physical and cognitive performance. Although both compounds have been widely investigated individually, evidence regarding their combined effects remains limited and inconsistent. Understanding whether caffeine and taurine produce synergistic or additive effects is important for clarifying their role in sports performance and supplementation strategies.
The present study is designed as a randomized, double-blind, placebo-controlled crossover trial to examine the isolated and combined effects of low-dose caffeine and taurine on anaerobic, neuromuscular, and cognitive performance in trained individuals. Participants will complete multiple experimental sessions under different supplementation conditions, including caffeine, taurine, their combination, and placebo. During each session, participants will undergo standardized performance assessments to evaluate anaerobic power, neuromuscular performance, and cognitive function. The crossover design allows each participant to serve as their own control, minimizing inter-individual variability. The findings of this study may provide further insight into the potential synergistic effects of caffeine and taurine supplementation on performance outcomes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- Participants complete multiple experimental sessions under different supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo) in a randomized crossover design. Each participant receives all interventions in separate sessions with appropriate washout periods.
| Arm | Type | Receives |
|---|---|---|
| Caffeine | Experimental | Dietary Supplement: Caffeine, Dietary Supplement: PlaceboParticipants receive caffeine at a dose of 2 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation. |
| Taurine | Experimental | Dietary Supplement: taurine, Dietary Supplement: PlaceboParticipants receive taurine at a dose of 10 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation. |
| Caffeine + Taurine | Experimental | Dietary Supplement: Caffeine + TaurineParticipants receive a combination of caffeine (2 mg/kg) and taurine (10 mg/kg) in capsule form 60 minutes prior to the performance testing session. Performance assessments include anaerobic, neuromuscular, and cognitive outcomes. |
| Plasebo (Maltodextrine 300 mg) | Placebo comparator | Dietary Supplement: PlaceboParticipants receive a placebo capsule containing maltodextrin (300 mg) 60 minutes prior to the performance testing session. The same performance tests are administered to allow comparison with the supplementation conditions. |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Male participants aged 18 to 25 years
- Regularly engaged in strength training at least three days per week for the previous 24 months
- Apparently healthy with no self-reported cardiovascular, metabolic, neurological, or musculoskeletal disorders
- Free from injuries affecting skeletal muscles, joints, or tendons during the previous two years
Key exclusion criteria (4 listed)
- Use of medications or dietary supplements that may influence physical or cognitive performance
- Known sensitivity or intolerance to caffeine or taurine
- Consumption of caffeine or other stimulants within 24 hours prior to the testing sessions
- Failure to comply with pre-testing instructions or study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CaffeineAlso: CAFCaffeine administered at a dose of 2 mg/kg body mass in capsule form, 60 minutes prior to performance testing. | Dietary supplement | Caffeine |
| taurineAlso: TAUTaurine administered at a dose of 10 mg/kg body mass in capsule form, 60 minutes prior to performance testing. | Dietary supplement | Taurine |
| Caffeine + TaurineAlso: CAF+TAUCombined supplementation of caffeine (2 mg/kg) and taurine (10 mg/kg) administered 60 minutes prior to testing. | Dietary supplement | Caffeine + Taurine |
| PlaceboAlso: PLAPlacebo capsule containing maltodextrin (300 mg) administered 60 minutes prior to testing. | Dietary supplement | Caffeine, Plasebo (Maltodextrine 300 mg), Taurine |
Primary outcome
Anaerobic Power
Time frame: 60 minutes after supplementation
Anaerobic power measured during the Wingate Anaerobic Test following supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo).
1 secondary outcome
Neuromuscular Performance
Time frame: 60 minutes after supplementation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Results publication: PubMed 42421135Kose Y, Ulas M, Atay E. Effects of combined low-dose caffeine and taurine on anaerobic, neuromuscular, and cognitive performance: a double-blind randomized placebo-controlled crossover study. BMC Sports Sci Med Rehabil. 2026 Jul 8. doi: 10.1186/s13102-026-01863-x. Online ahead of print.
- Open Scince FrameworkLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant-level data will not be publicly shared. Aggregated data supporting the findings of this study may be available from the corresponding author upon reasonable request.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yakup Köse, MsC principal investigator
Burdur Mehmet Akif Ersoy University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine, taurine and Caffeine + Taurine in people with Anaerobic Performance Neuromuscular Performance Cognitive Performance, run by Ankara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anaerobic Power (time frame: 60 minutes after supplementation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07466654, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.